Terms: = Ovarian cancer AND CHD4, Mi2-BETA, 1108, ENSG00000111642, Mi-2b, DKFZp686E06161, Q14839
21 results:
1. Platinum-free Interval May Predict Duration of Maintenance Bevacizumab and Survival in Platinum-sensitive Recurrent ovarian cancer.
Oh SH; Park SJ; Lee S; Lee S; Kim HS
In Vivo; 2024; 38(1):467-473. PubMed ID: 38148089
[TBL] [Abstract] [Full Text] [Related]
2. The epigenetic factor chd4 contributes to metastasis by regulating the EZH2/β-catenin axis and acts as a therapeutic target in ovarian cancer.
Wang J; Zhong F; Li J; Yue H; Li W; Lu X
J Transl Med; 2023 Jan; 21(1):38. PubMed ID: 36681835
[TBL] [Abstract] [Full Text] [Related]
3. chd4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of chd4 inhibition as a combination therapy with platinum agents.
Oyama Y; Shigeta S; Tokunaga H; Tsuji K; Ishibashi M; Shibuya Y; Shimada M; Yasuda J; Yaegashi N
PLoS One; 2021; 16(6):e0251079. PubMed ID: 34161330
[TBL] [Abstract] [Full Text] [Related]
4. Cytoplasmic ADP-ribosylation levels correlate with markers of patient outcome in distinct human cancers.
Aimi F; Moch H; Schraml P; Hottiger MO
Mod Pathol; 2021 Aug; 34(8):1468-1477. PubMed ID: 33742140
[TBL] [Abstract] [Full Text] [Related]
5. Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma.
Li L; Yue P; Song Q; Yen TT; Asaka S; Wang TL; Beavis AL; Fader AN; Jiao Y; Yuan G; Shih IM; Song Y
J Pathol; 2021 Jan; 253(1):119-128. PubMed ID: 33016334
[TBL] [Abstract] [Full Text] [Related]
6. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.
Mittermeier T; Farrant C; Wise MR
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012658. PubMed ID: 32909630
[TBL] [Abstract] [Full Text] [Related]
7. Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma.
Cuevas D; Valls J; Gatius S; Roman-Canal B; Estaran E; Dorca E; Santacana M; Vaquero M; Eritja N; Velasco A; Matias-Guiu X
Virchows Arch; 2019 May; 474(5):585-598. PubMed ID: 30710169
[TBL] [Abstract] [Full Text] [Related]
8. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
[TBL] [Abstract] [Full Text] [Related]
9. Radiation-associated breast cancer and gonadal hormone exposure: a report from the Childhood cancer Survivor Study.
Moskowitz CS; Chou JF; Sklar CA; Barnea D; Ronckers CM; Friedman DN; Neglia JP; Turcotte L; Howell RM; Henderson TO; Armstrong GT; Leisenring WM; Robison LL; van Leeuwen FE; Pike MC; Oeffinger KC
Br J Cancer; 2017 Jul; 117(2):290-299. PubMed ID: 28632729
[TBL] [Abstract] [Full Text] [Related]
10. Prediction of Site-Specific Tumor Relapses in Patients With Stage I-II Endometrioid Endometrial cancer.
Tuomi T; Pasanen A; Leminen A; Bützow R; Loukovaara M
Int J Gynecol Cancer; 2017 Jun; 27(5):923-930. PubMed ID: 28498250
[TBL] [Abstract] [Full Text] [Related]
11. Prediction of lymphatic dissemination in endometrioid endometrial cancer: Comparison of three risk-stratification models in a single-institution cohort.
Tuomi T; Pasanen A; Leminen A; Bützow R; Loukovaara M
Gynecol Oncol; 2017 Mar; 144(3):510-514. PubMed ID: 28069268
[TBL] [Abstract] [Full Text] [Related]
12. Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma.
García-Sanz P; Triviño JC; Mota A; Pérez López M; Colás E; Rojo-Sebastián A; García Á; Gatius S; Ruiz M; Prat J; López-López R; Abal M; Gil-Moreno A; Reventós J; Matias-Guiu X; Moreno-Bueno G
Int J Cancer; 2017 Apr; 140(7):1551-1563. PubMed ID: 27997699
[TBL] [Abstract] [Full Text] [Related]
13. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Zhao S; Bellone S; Lopez S; Thakral D; Schwab C; English DP; Black J; Cocco E; Choi J; Zammataro L; Predolini F; Bonazzoli E; Bi M; Buza N; Hui P; Wong S; Abu-Khalaf M; Ravaggi A; Bignotti E; Bandiera E; Romani C; Todeschini P; Tassi R; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Facchetti F; Falchetti M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Mane S; Angioli R; Terranova C; Quick CM; Edraki B; Bilgüvar K; Lee M; Choi M; Stiegler AL; Boggon TJ; Schlessinger J; Lifton RP; Santin AD
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12238-12243. PubMed ID: 27791010
[TBL] [Abstract] [Full Text] [Related]
14. Improved Detection Rate of ovarian cancer Using a 2-Step Triage Model of the Risk of Malignancy Index and Expert Sonography in an Outpatient Screening Setting.
Manegold-Brauer G; Buechel J; Knipprath-Mészaros A; Schoetzau A; Hacker NF; Tercanli S; Lapaire O; Heinzelmann-Schwarz V
Int J Gynecol Cancer; 2016 Jul; 26(6):1062-9. PubMed ID: 27177281
[TBL] [Abstract] [Full Text] [Related]
15. Surgical wait time: A new health indicator in women with endometrial cancer.
Strohl AE; Feinglass JM; Shahabi S; Simon MA
Gynecol Oncol; 2016 Jun; 141(3):511-515. PubMed ID: 27103178
[TBL] [Abstract] [Full Text] [Related]
16. High Expression of miR-532-5p, a Tumor Suppressor, Leads to Better Prognosis in ovarian cancer Both In Vivo and In Vitro.
Wang F; Chang JT; Kao CJ; Huang RS
Mol Cancer Ther; 2016 May; 15(5):1123-31. PubMed ID: 26873729
[TBL] [Abstract] [Full Text] [Related]
17. Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor chd4.
Guillemette S; Serra RW; Peng M; Hayes JA; Konstantinopoulos PA; Green MR; Cantor SB
Genes Dev; 2015 Mar; 29(5):489-94. PubMed ID: 25737278
[TBL] [Abstract] [Full Text] [Related]
18. A systematic comparison of the anti-tumoural activity and toxicity of the three Adv-TKs.
Gao Q; Chen C; Ji T; Wu P; Han Z; Fang H; Li F; Liu Y; Hu W; Gong D; Zhang Z; Wang S; Zhou J; Ma D
PLoS One; 2014; 9(4):e94050. PubMed ID: 24722669
[TBL] [Abstract] [Full Text] [Related]
19. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes.
Le Gallo M; O'Hara AJ; Rudd ML; Urick ME; Hansen NF; O'Neil NJ; Price JC; Zhang S; England BM; Godwin AK; Sgroi DC; ; Hieter P; Mullikin JC; Merino MJ; Bell DW
Nat Genet; 2012 Dec; 44(12):1310-5. PubMed ID: 23104009
[TBL] [Abstract] [Full Text] [Related]
20. [Relationship between hormone therapy in women with ovarian malignancy and prognosis].
Li L; Pan ZM; Chen XQ; Gao K; Zhang W; Luo Y; Yao ZQ; Liang XQ; Huang W; Yao DS
Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):843-8. PubMed ID: 19087569
[TBL] [Abstract] [Full Text] [Related]
[Next]
